Work

Cost-effectiveness of second- or third-line treatment with tisotumab vedotin for metastatic or recurrent cervical cancer

Year: 2025

Type: article

Source: Expert Review of Pharmacoeconomics & Outcomes Research

DOI: 10.1080/14737167.2025.2603941

Authors: María del Pilar Briceño-Casado, Adrián Sánchez Vegas, Emilio Jesús Alegre-Del-Rey, Antonio Olry de Labry Lima

Institutions: Hospital Universitario Puerto Real, Hospital Universitario de Valme, Universidad de Granada, Instituto de Salud Carlos III, Instituto de Investigación Biosanitaria de Granada, Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Andalusian School of Public Health

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417276632

FWCI:

Cites: 20

Cited by:

Related to: